Background: The purpose of this study was to evaluate the in vitro adherence of different yeasts, isolated from vaginal exudates of patients with vulvovaginal candidiasis (VVC), to the combined contraceptive vaginal ring--NuvaRing.
Study Design: Four isolates of Candida sp. and one isolate of Saccharomyces cerevisiae were used. Adherence assays were carried out through colony-forming units per milliliter (CFU/mL), radiolabeled quantification and scanning electron microscopy (SEM) of the ring, and the cell surface hydrophobicity (CSH) of the yeasts was determined.
Results: All the yeasts were capable of adhering to the vaginal ring, as determined by CFU/mL and in the radiolabeled assay. CSH was compatible with the adherence by CFU/mL.
Conclusion: SEM proved the adhesion, which was different between Candida albicans and C. tropicalis. The adherence of the tested yeasts to the ring could potentially facilitate the development of VVC and recurrent VVC in susceptible patients using this contraceptive method.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.contraception.2007.07.012 | DOI Listing |
J Minim Invasive Gynecol
January 2025
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:
Study Subject: To investigate the impact of preoperative hormonal medication, including combined oral contraceptives (COCs) or dienogest, on operative findings in ovarian endometrioma surgery.
Design: A single-center, retrospective study.
Setting: Department of Gynecology, Samsung Medical Center, Republic of Korea.
Objectives: Human papillomavirus (HPV) is the leading cause of cervical cancer, with adolescent girls and young women (AGYW) in sub-Saharan Africa carrying a disproportionately high burden of infection. Hormonal contraceptives may influence HPV acquisition, persistence, and clearance, but evidence remains inconclusive. This sub-study aimed to evaluate the impact of different hormonal contraceptives on HPV prevalence and genotype distribution in AGYW.
View Article and Find Full Text PDFContraception
January 2025
Division of Endocrinology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California; Clinical and Translational Science Institute, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California.
While there are several easy-to-use reversible female contraceptives, little is available for men. Introduction of novel, cost-effective male contraceptives could have important downstream global health and economic benefits. Currently, nearly half of all pregnancies globally are unintended, with many resulting in unsafe abortions, a significant burden for women and families in many countries.
View Article and Find Full Text PDFEur J Obstet Gynecol Reprod Biol
January 2025
Faculty of Medical Sciences of Minas Gerais Belo Horizonte Brazil.
Objective: Endometriosis involves the growth of endometrium-like cells outside the uterus, affecting reproductive-aged women. Symptoms such as dysmenorrhea, pelvic pain, and infertility significantly impair quality of life. Among therapeutic options, progestogens have demonstrated efficacy in managing pain and reducing recurrence rates.
View Article and Find Full Text PDFExpert Opin Pharmacother
January 2025
Obstetrics and Gynecology Department Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
Introduction: Endometriosis is a chronic inflammatory estrogen-dependent disease affecting 10% of women worldwide leading to chronic pelvic pain and infertility which may be treated clinically or surgically.
Areas Covered: Current literaure was reviewed using the keywords 'gonadotropin releasing hormone agonists (GnRHa),' 'endometriosis,' 'infertility' and 'chronic pelvic pain.' Relevant papers prioritizing randomized controlled clinical trials (RCT), systematic reviews, meta-analyses, as well as international guidelines were evaluated.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!